HK51197A - Platelet blocking peptides - Google Patents

Platelet blocking peptides

Info

Publication number
HK51197A
HK51197A HK51197A HK51197A HK51197A HK 51197 A HK51197 A HK 51197A HK 51197 A HK51197 A HK 51197A HK 51197 A HK51197 A HK 51197A HK 51197 A HK51197 A HK 51197A
Authority
HK
Hong Kong
Prior art keywords
blocking peptides
platelet
oligopeptides
platelet blocking
fibrinogen
Prior art date
Application number
HK51197A
Inventor
Israel F Charo
Laurence A Fitzgerald
David R Phillips
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Publication of HK51197A publication Critical patent/HK51197A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides oligopeptides corresponding to regions of the GPIIIa protein, which are capable of specifically binding aggregation mediators, such as fibrinogen. The oligopeptides will typically comprise at least about 5 to 20 amino acids, and are thus non-immunogenic and easy to produce, formulate and administer.
HK51197A 1988-06-30 1997-04-17 Platelet blocking peptides HK51197A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21364188A 1988-06-30 1988-06-30
US33696289A 1989-04-12 1989-04-12

Publications (1)

Publication Number Publication Date
HK51197A true HK51197A (en) 1997-04-25

Family

ID=26908261

Family Applications (1)

Application Number Title Priority Date Filing Date
HK51197A HK51197A (en) 1988-06-30 1997-04-17 Platelet blocking peptides

Country Status (7)

Country Link
US (1) US5705606A (en)
EP (1) EP0422125B1 (en)
JP (1) JP2892726B2 (en)
AT (1) ATE144535T1 (en)
DE (1) DE68927379T2 (en)
HK (1) HK51197A (en)
WO (1) WO1990000178A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2547263B2 (en) * 1987-12-10 1996-10-23 ラ・ジョラ・キャンサー・リサーチ・ファウンデーション A conformationally stabilized cell attachment peptide
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US5795867A (en) * 1989-06-16 1998-08-18 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
US5612311A (en) 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5648330A (en) * 1990-04-06 1997-07-15 La Jolla Cancer Research Foundation Method and composition for treating vascular graft occlusion
DK0527798T3 (en) * 1990-04-06 1997-12-15 Jolla Cancer Res Found Method and composition for the treatment of thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
IE62682B1 (en) * 1990-12-03 1995-02-22 Scripps Research Inst Method and compositions for diagnosing chronic immune thrombocytopenic purpura
US5177188A (en) * 1990-12-03 1993-01-05 The Scripps Research Institute Methods and compositions for diagnosing chronic immune thrombocytopenic purpura
WO1992017492A1 (en) * 1991-04-05 1992-10-15 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a?
US5589458A (en) * 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
JPH09504554A (en) * 1993-12-27 1997-05-06 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント，インコーポレーテッド Methods and compositions for inhibiting thrombus formation
US6808698B1 (en) 1999-03-26 2004-10-26 Bristol-Myers Squibb Pharma Company Method for localization of blood clots
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US6685914B1 (en) 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
US7615527B2 (en) * 2001-07-06 2009-11-10 Oregon Health & Science University Peptides which modulate blood coagulation and methods of use thereof
GB0315754D0 (en) * 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4849407A (en) * 1986-08-13 1989-07-18 Zymogenetics, Inc. Biologically active mosaic proteins
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4801542A (en) * 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4789734A (en) * 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
EP0259632B1 (en) * 1986-08-13 1995-12-13 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
DE3855504T2 (en) * 1987-04-22 1997-01-23 Chiron Corp Recombinant production of A chain polypeptides from PDGF
EP0325224B1 (en) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5149780A (en) * 1988-10-03 1992-09-22 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
WO1993007169A1 (en) * 1991-10-04 1993-04-15 Chiron Corporation Peptide inhibitors of platelet adhesion

Also Published As

Publication number Publication date
JP2892726B2 (en) 1999-05-17
US5705606A (en) 1998-01-06
EP0422125A1 (en) 1991-04-17
WO1990000178A1 (en) 1990-01-11
EP0422125A4 (en) 1992-07-08
ATE144535T1 (en) 1996-11-15
DE68927379D1 (en) 1996-11-28
EP0422125B1 (en) 1996-10-23
DE68927379T2 (en) 1997-02-20
JPH04503661A (en) 1992-07-02

Similar Documents

Publication Publication Date Title
HK51197A (en) Platelet blocking peptides
DK1175909T3 (en) Therapeutic compositions of antibodies and antisense nucleic acids against Serrate
ATE380875T1 (en) CHIMERIC PROTEINS TO AVOID COMPLEMENT ACTIVATION
DE69838143D1 (en) ANTIMICROBIAL PEPTIDES
ES2063113T3 (en) VIBORA POISON POLYPEPTIDES AND GENETIC EXPRESSION.
DE69715181D1 (en) PEPTIDE THE SOLUBLE FORM OF ACETYLCHOLINESTERASE WITH ACTIVITY AS A CALCIUM CHANNEL MODULATOR
DE68917837D1 (en) Peptide compounds.
ATE211765T1 (en) NEW FAMILY OF PROTEASE INHIBITORS AND OTHER BIOLOGICALLY ACTIVE SUBSTANCES
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
ES2063161T3 (en) MODIFIED PROTEINS.
EP0730469A4 (en) Modified truncated complement system regulators
EP0723016A3 (en) Activating factor of leukocytes
GR3005408T3 (en)
SE9402253D0 (en) Process

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)